Brandon Capital is Australasia's leading life science venture capital firm, investing in biomedical breakthroughs from early-stage seed through to expansion capital. Headquartered in Melbourne with offices in Sydney, San Francisco, and London, the firm manages over A$1 billion across six funds.
41% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 4 prior). Average disclosed round size is $54.6M (across 23 rounds with reported amounts).
Portfolio
23
Fund Size
$290M
Top Stage
Series B
Last 12 Mo
2
Team
Chris Smith
Partner
David Fisher
Partner Emeritus
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
32 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Lumonus | Series B | — | Mar 2026 |
| OOncoRes Medical | Unknown | — | Feb 2026 |
 NRG Therapeutics | Series B | $50M | Sep 2025 |
 Allay Therapeutics | Series D | $57.5M | Jun 2025 |
| PPolyActiva | Series C | — | May 2025 |
| MMirugen | Seed | $4.5M | Jan 2025 |
 CatalYm | Series D | $150M | Jul 2024 |
 Myricx Bio | Series A | $90M | Jul 2024 |
 Pheon Therapeutics | Series B | $120M | May 2024 |
 Pathios Therapeutics | Series B | $25M | Apr 2024 |
 Entact Bio | Series A | $81M | Dec 2022 |
| NRG Therapeutics | Series A | — | Nov 2022 |
| Pheon Therapeutics | Series A | $68M | Sep 2022 |
 Aravax | Series B | $42.2M | Jan 2022 |
| EEna Respiratory | Series B | — | Jan 2021 |
| GGeorge Medicine | Unknown | $20M | Jan 2020 |
| Myricx Bio | Seed | — | Nov 2019 |
| GGlobal Kinetics Corporation | Unknown | $7.8M | Apr 2018 |
| CCincera Therapeutics | Unknown | — | Feb 2018 |
| EElastagen | Series B | $14M | Jan 2016 |
| GGlobal Kinetics Corporation | Unknown | $14.8M | Jun 2015 |
| SSpinifex Pharmaceuticals | Unknown | $45M | Apr 2014 |
| SSpinifex Pharmaceuticals | Series C | $45M | Jan 2014 |
| SSpinifex | Series C | $45M | Jan 2014 |
| PPolyActiva | Series B | $9.2M | Feb 2013 |
Page 1 of 2
Top Co-Investors
Canaan Partners6 shared
Abingworth LLP3 shared
Omega Funds3 shared
UniQuest3 shared
Atlas Venture2 shared
Forbion2 shared
Tenmile2 shared
Eli Lilly and Company2 shared
Sofinnova Partners2 shared
Novo Capital2 shared
Novo Holdings A/S2 shared
BVF Partners L.P.1 shared
Lightspeed Venture Partners1 shared
TCG1 shared
Perceptive Advisors1 shared
Sanofi Ventures1 shared
Catalio Capital Management1 shared
Eventide Asset Management1 shared
T. Rowe Price1 shared
Last updated: 9 September 2026